HCPCS Code J0897: Injection, Denosumab, 1 mg

J0897 is often used as part of osteoporosis therapy to help strengthen bones and reduce the risk of fractures. It may be prescribed to Medicare beneficiaries who are at high risk for fracture, particularly in cases of osteoporosis without a current pathological fracture or in patients who have experienced a pathological fracture of the right shoulder, fracture of the right femur initially, or fracture of the right forearm initially. By decreasing bone resorption and improving bone density, this treatment helps prevent complications such as multiple myeloma–related bone damage or bone metastasis.

Yes. J0897 is appropriate for conditions such as bone metastasis from solid tumors or multiple myeloma, where there is a high risk for fracture and severe morbidity. It is often used alongside androgen deprivation therapy or adjuvant aromatase inhibitor therapy in cancer patients to protect bone density.

When billing, documentation should clearly state the type and site of fracture, such as fracture right shoulder initial, right femur initial encounter, right forearm initial encounter, or ankle and foot initial. For follow-up cases, terms like ankle and foot sequela or left ankle and foot may apply.